- Home
- SRRK
as 10-07-2025 3:29pm EST
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 3.0B | IPO Year: | 2018 |
| Target Price: | $45.25 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.71 - $46.98 | Next Earning Date: | 11-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1996.18% |
Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Sep 22 '25 | Sell | $30.67 | 3,353 | $102,846.23 | 108,964 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Sep 16 '25 | Sell | $33.52 | 3,178 | $106,526.56 | 108,964 | |
| Peng Katie | SRRK | Director | Sep 16 '25 | Sell | $32.84 | 1,006 | $32,725.69 | 33,990 | |
| Parlavecchio Caryn | SRRK | CHRO | Aug 18 '25 | Sell | $31.17 | 2,178 | $67,880.20 | 155,464 |
Latest Scholar Rock Holding Corporation News
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Scholar Rock (SRRK): Assessing Valuation Following FDA Setback for Apitegromab Approval
Investor's Business Daily
15 days ago
Scholar Rock, A Top 10% Stock, Reverses Higher Despite A Surprise Setback
MT Newswires
15 days ago
HC Wainwright Adjusts Price Target on Scholar Rock Holding to $44 From $50, Maintains Buy Rating
MT Newswires
15 days ago
Sector Update: Health Care Stocks Advance Premarket Tuesday
MT Newswires
15 days ago
Sector Update: Health Care
MT Newswires
15 days ago
Scholar Rock Faces FDA Setback on SMA Drug Due to Manufacturing Site Issues
Reuters
15 days ago
US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall
Business Wire
15 days ago
FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility
Compare SRRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.